Olympus Announces Full Market Release of AI-Powered Emphysema Screening Program
https://www.olympusamerica.com/press-release/2025-06-09/olympus-announces-full-market-release-ai-powered-emphysema-screening
CENTER VALLEY, Pa., (June 9, 2025) – Olympus Corp., a global medical technology company committed to making people’s lives healthier, safer and more fulfilling, announced today the full market release of its AI-driven emphysema screening program, SeleCT™ Screening.
The SeleCT™ Screening AI platform, powered by 4DMedical, helps identify severe emphysema patients who may benefit from a clinically proven and minimally invasive procedure to improve lung function called bronchoscopic lung volume reduction (BLVR).
SeleCT Screening automatically reviews existing chest computed tomography (CT) scans throughout a health system to help identify patients who may benefit from BLVR with endobronchial valves such as the Spiration™ Valve System. Physicians are notified if a potentially qualified patient is identified so that they can be contacted for further evaluation for the Spiration Valve.
(20min delay)